Haloperidol induced Parkinson’s disease mice model and motor-function modulation with Pyridine-3-carboxylic acid

Main Article Content

Atif Saeed Lubna Shakir Mahtab A. Khan Arsalan Ali Awais Ali Zaidi

Abstract

Introduction: Motor-function modulation through Pyridine-3-carboxylic acid was assessed against. Haloperidol induced Parkinson’s disease (PD) in albino-mice. The objectives of this study were to test the effect of Haloperidol in development of PD, effectiveness of Pyridine-3-carboxylic acid in mice and evaluation of the motor-function changes in mice before and after treatment.

Methods: The study was divided into 3 phases: During Phase-I (randomization), all the subjects were randomly divided into 4 groups and trained for wire-hanging, grip strength, vertical rod and swim tests for 1 week. During Phase-II (disease induction), PD was induced by intra-peritoneal (ip) administration of Haloperidol (HP) in a dose of 1 mg/kg/d for 7 days. Group-A comprised of healthy controls, Group-B (Diseased), Group-C (HP+Pyridine-3-carboxylic acid 7.15 mg/kg/d) and Group-D (HP+Pyridine-3-carboxylic acid15 mg/kg/d).

Results: Pyridine-3-carboxylic acid treatment continued for 5 weeks. During Phase-III the above mention tests were performed and the effects of Pyridine-3-carboxylic acid were recorded. However, in swim test Group D is statistically insignificant as compared to Group B (p=0.284). In recent study, haloperidol is found to be effective in inducing motor function anomalies likewise in Parkinson’s disease including movement slowness, difficulties with gait and balance.

Conclusion: oral administration of Pyridine-3-carboxylic acid improved Motor-function changes in diseased mice. Therefore, it is concluded that Pyridine-3-carboxylic acid may help to alleviate PD symptoms.

References

Aartsma-Rus, A., and van Putten, M. (2014). Assessing functional performance in the mdx mouse model. JoVE (Journal of Visualized Experiments), e51303-e51303.
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations. Journal of the neurological sciences 20, 415-455.
Burger, M.E., Fachinetto, R., Zeni, G., and Rocha, J.B. (2005). Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacology Biochemistry and Behavior 81, 608-615.
Chauhan, A., Chauhan, V., Brown, W.T., and Cohen, I. (2004). Oxidative stress in autism: Increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin-the antioxidant proteins. Life sciences 75, 2539-2549.
Creese, I., Burt, D.R., and Snyder, S.H. (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. science 192, 481-483.
Elkashef, A.M., and Wyatt, R.J. (1999). Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophrenia bulletin 25, 731-740.
Fernagut, P.O., Diguet, E., Labattu, B., and Tison, F. (2002). A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. Journal of neuroscience methods 113, 123-130.
Gurakar, A., Hoeg, J.M., Kostner, G., Papadopoulos, N.M., and Brewer, H.B. (1985). Levels of lipoprotein Lp (a) decline with neomycin and niacin treatment. Atherosclerosis 57, 293-301.
Hirtz, D., Thurman, D., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A., and Zalutsky, R. (2007). How common are the “common” neurologic disorders? Neurology 68, 326-337.
Kempster, P.A., Hurwitz, B., and Lees, A.J. (2007). A new look at James Parkinson's Essay on the Shaking Palsy. Neurology 69, 482-485.
Klein, T.J., and Lewis, M.A. (2012). A physical model of sensorimotor interactions during locomotion. Journal of neural engineering 9, 046011.
Klockgether, T. (2004). Parkinson’s disease: clinical aspects. Cell and tissue research 318, 115-120.
Kobayashi, T., Araki, T., Itoyama, Y., Takeshita, M., Ohta, T., and Oshima, Y. (1997). Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice. Life sciences 61, 2529-2538.
Manikandaselvi, S., Mahalakshmi, R., Thinagarbabu, R., and Angumeenal, A. (2012). Neuroprotective activity of S-Allylcysteine on Haloperidol induced Parkinson’s disease in albino mice. Int J Pharm Technol Res 4, 669-675.
Molina, J., Jiménez‐Jiménez, F., Navarro, J., Vargas, C., Gomez, P., Benito‐León, J., Ortí‐Pareja, M., Cisneros, E., and Arenas, J. (1996). Cerebrospinal fluid nitrate levels in patients with Parkinson's disease. Acta neurologica scandinavica 93, 123-126.
Morris, M.C., Evans, D.A., Bienias, J.L., Scherr, P.A., Tangney, C.C., Hebert, L.E., Bennett, D., Wilson, R.S., and Aggarwal, N. (2004). Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline. Journal of Neurology, Neurosurgery & Psychiatry 75, 1093-1099.
Naidu, P.S., Singh, A., and Kulkarni, S.K. (2003). Quercetin, a bioflavonoid, attenuates haloperidol-induced orofacial dyskinesia. Neuropharmacology 44, 1100-1106.
Pavan, T., Manasa, K., Tamilanban, T., and Alagarsamy, V. (2015). Effect of Methanolic extract of Canscora decussata on Haloperidol-Induced Motor deficits in Albino mice. Int J Pharm Sci Rev Res 35, 7-11.
Pongiya, U.D., Kandanath, B.M., and Rao, Y.R. (2014). Efficacy of hypericum hookerianum in reversing the symptoms of haloperidol induced tardive dyskenesia, catatonia and catalepsy in swiss albino mice-behavioural analysis report. World Journal of Pharmacy And Pharmaceutical Sciences 3, 1682-1705.
Rahman, M., Muhammad, S., Khan, M.A., Chen, H., Ridder, D.A., Muller-Fielitz, H., Pokorna, B., Vollbrandt, T., Stolting, I., Nadrowitz, R., et al. (2014). The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nature communications 5, 3944.
Scholtissen, B., Verhey, F., Steinbusch, H., and Leentjens, A. (2006). Serotonergic mechanisms in Parkinson’s disease: opposing results from preclinical and clinical data. Journal of neural transmission 113, 59-73.
Sheidaei, H. (2010). Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT1A recaptors. DARU: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences 18, 41.
Wang, S., Hu, L.-f., Yang, Y., Ding, J.-h., and Hu, G. (2005). Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson's disease: implications for treating Parkinson's disease? Neuropharmacology 48, 984-992.
Zaidi, A.A., Khan, T.A., Shakir, L., Khan, M.A., Yousaf, M., and Ali, A. (2016a). Evaluation of C. cassia Effectiveness in Behavioral Modulation of Haloperidol Induced Parkinson’s Disease (Mice Model). British Journal of Pharmaceutical Research 6, 1-7.
Zaidi, A.A., Shakir, L., Khan, T.A., Khan, M.A., Ali, A., and Rehman, A.U. (2016b). Haloperidol leads to torse de pointes in schizophrenic pool. European Journal of Pharmaceutica And Medical Research 3, 84-91.

Downloads

Download data is not yet available.

Article Details

How to Cite
SAEED, Atif et al. Haloperidol induced Parkinson’s disease mice model and motor-function modulation with Pyridine-3-carboxylic acid. Biomedical Research and Therapy, [S.l.], v. 4, n. 05, p. 1305-1317, may 2017. ISSN 2198-4093. Available at: <http://www.bmrat.org/index.php/BMRAT/article/view/169>. Date accessed: 23 oct. 2017. doi: https://doi.org/10.15419/bmrat.v4i05.169.
Section
Research articles

Most read articles by the same author(s)